Overview
- A JAMA Network Open review of more than 840,000 U.S. cases from 2006 to 2023 linked GLP-1 receptor agonist use to lower 10-year death and fewer recurrences, with the largest drop in patients with obesity or type 2 diabetes.
- Among patients with obesity, the study reported a 65% lower risk of death over 10 years and a 56% lower risk of recurrence.
- University of Southampton and Breast Cancer Now experts called the findings promising yet cautioned that the observational design cannot separate drug effects from weight loss or patient differences.
- Study authors said they plan randomized clinical trials and mechanistic research to test whether the drugs themselves drive the observed benefits.
- GLP-1 drugs are approved for diabetes and weight management and use has surged since 2020, with a RAND report estimating about 12% of Americans have used them for weight loss, and the paper disclosed ties to the TriNetX data network.